Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 315-318, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lydiard, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lydiard, R. B.

Clinical Chemistry, Vol 40, 315-318, Copyright © 1994 by American Association for Clinical Chemistry

Neuropeptides and anxiety: focus on cholecystokinin

RB Lydiard
Institute of Psychiatry, Medical University of South Carolina, Charleston 29425.

Cholecystokinin (CCK), a gastrin-like neuropeptide, exists in the central nervous system in several forms. The octapeptide (CCK-8) occurs in predominantly sulfated form (CCK-8S), and the tetrapeptide (CCK-4) occurs in smaller but significant quantities. This review highlights recent developments in preclinical and clinical research into the potential role for CCK in mediating anxiety states. Relevant animal and human studies of administration of CCK agonists are discussed, as well as recent data regarding the concentration of CCK-8S in cerebrospinal fluid from patients with panic disorder, bulimia nervosa, and obsessive compulsive disorder. Finally, the development of agents that specifically antagonize CCK receptors will be described, as will potential therapeutic uses for these new compounds.


The following articles in journals at HighWire Press have cited this article:


Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Chen, A. Nakajima, C. Meacham, and Y.-P. Tang
Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.
PNAS, March 7, 2006; 103(10): 3881 - 3886.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. K. Bhattacharya, K. S. Satyan, and A. Chakrabarti
Anxiogenic action of caffeine: an experimental study in rats
J Psychopharmacol, January 1, 1997; 11(3): 219 - 224.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. K. Bhattacharya, P. J. R. Mohan Rao, and A. P. Sen
Anxiogenic activity of intraventricularly administered bradykinin in rats
J Psychopharmacol, January 1, 1995; 9(4): 348 - 354.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.